Detalles de la búsqueda
1.
The Antibody Registry: ten years of registering antibodies.
Nucleic Acids Res
; 51(D1): D358-D367, 2023 01 06.
Artículo
en Inglés
| MEDLINE | ID: mdl-36370112
2.
Structure-based design, SAR analysis and antitumor activity of PI3K/mTOR dual inhibitors from 4-methylpyridopyrimidinone series.
Bioorg Med Chem Lett
; 23(9): 2787-92, 2013 May 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-23506825
3.
Discovery of 2-((1H-benzo[d]imidazol-1-yl)methyl)-4H-pyrido[1,2-a]pyrimidin-4-ones as novel PKM2 activators.
Bioorg Med Chem Lett
; 23(11): 3358-63, 2013 Jun 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-23622982
4.
Design of oxobenzimidazoles and oxindoles as novel androgen receptor antagonists.
Bioorg Med Chem Lett
; 22(7): 2572-8, 2012 Apr 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-22377517
5.
Structural modifications of a 3-methoxy-2-aminopyridine compound to reduce potential for mutagenicity and time-dependent drug-drug interaction.
Bioorg Med Chem Lett
; 22(24): 7605-9, 2012 Dec 15.
Artículo
en Inglés
| MEDLINE | ID: mdl-23116892
6.
Discovery of 3-aryloxy-lactam analogs as potent androgen receptor full antagonists for treating castration resistant prostate cancer.
Bioorg Med Chem Lett
; 22(2): 1230-6, 2012 Jan 15.
Artículo
en Inglés
| MEDLINE | ID: mdl-22197140
7.
Structure-Based Drug Design and Synthesis of PI3Kα-Selective Inhibitor (PF-06843195).
J Med Chem
; 64(1): 644-661, 2021 01 14.
Artículo
en Inglés
| MEDLINE | ID: mdl-33356246
8.
Discovery of N-((3R,4R)-4-Fluoro-1-(6-((3-methoxy-1-methyl-1H-pyrazol-4-yl)amino)-9-methyl-9H-purin-2-yl)pyrrolidine-3-yl)acrylamide (PF-06747775) through Structure-Based Drug Design: A High Affinity Irreversible Inhibitor Targeting Oncogenic EGFR Mutants with Selectivity over Wild-Type EGFR.
J Med Chem
; 60(7): 3002-3019, 2017 04 13.
Artículo
en Inglés
| MEDLINE | ID: mdl-28287730
9.
Discovery of 1-{(3R,4R)-3-[({5-Chloro-2-[(1-methyl-1H-pyrazol-4-yl)amino]-7H-pyrrolo[2,3-d]pyrimidin-4-yl}oxy)methyl]-4-methoxypyrrolidin-1-yl}prop-2-en-1-one (PF-06459988), a Potent, WT Sparing, Irreversible Inhibitor of T790M-Containing EGFR Mutants.
J Med Chem
; 59(5): 2005-24, 2016 Mar 10.
Artículo
en Inglés
| MEDLINE | ID: mdl-26756222
10.
Discovery of a novel class of exquisitely selective mesenchymal-epithelial transition factor (c-MET) protein kinase inhibitors and identification of the clinical candidate 2-(4-(1-(quinolin-6-ylmethyl)-1H-[1,2,3]triazolo[4,5-b]pyrazin-6-yl)-1H-pyrazol-1-yl)ethanol (PF-04217903) for the treatment of cancer.
J Med Chem
; 55(18): 8091-109, 2012 Sep 27.
Artículo
en Inglés
| MEDLINE | ID: mdl-22924734
11.
Systematic structure modifications of imidazo[1,2-a]pyrimidine to reduce metabolism mediated by aldehyde oxidase (AO).
J Med Chem
; 54(21): 7705-12, 2011 Nov 10.
Artículo
en Inglés
| MEDLINE | ID: mdl-21955208
12.
Structure based drug design of crizotinib (PF-02341066), a potent and selective dual inhibitor of mesenchymal-epithelial transition factor (c-MET) kinase and anaplastic lymphoma kinase (ALK).
J Med Chem
; 54(18): 6342-63, 2011 Sep 22.
Artículo
en Inglés
| MEDLINE | ID: mdl-21812414
13.
Discovery of aryloxy tetramethylcyclobutanes as novel androgen receptor antagonists.
J Med Chem
; 54(21): 7693-704, 2011 Nov 10.
Artículo
en Inglés
| MEDLINE | ID: mdl-21936524
Resultados
1 -
13
de 13
1
Próxima >
>>